Suppr超能文献

5-羟色胺1(5-HT1)激动剂舒马曲坦对食管动力障碍患者食管运动模式的影响。

Effect of the 5-HT1 agonist sumatriptan on oesophageal motor pattern in patients with ineffective oesophageal motility.

作者信息

Grossi L, Ciccaglione A F, Marzio L

机构信息

Department of Medicine and Sciences of Aging, School of Gastroenterology, c/o Pierangeli Clinic, G d'Annunzio University of Chieti, Pescara, Italy. l.grossi@unich

出版信息

Neurogastroenterol Motil. 2003 Feb;15(1):9-14. doi: 10.1046/j.1365-2982.2003.00380.x.

Abstract

The 5-HT1 agonist sumatriptan (SUM) elicits an increase in amplitude of oesophageal motor waves and of lower oesophageal sphincter (LOS) tone in healthy subjects. The aim of the study was to evaluate whether such an effect occurs also in patients with ineffective oesophageal motility (IOM). 16 patients (nine males and seven females, age range 34-55 years) with chest pain and mild to moderate dysphagia were studied; all had undergone previous cardiologic, radiologic and upper gastrointestinal endoscopic exams that were normal. An oesophageal manometry was performed using an electronic probe to record swallows, oesophageal, LOS and gastric motility. The patients whose motor pattern were compatible with IOM (>30% of motor waves with amplitude <30 mmHg and/or non-transmitted) received SUM or placebo 6 mg s.c., injected in the morning and in the afternoon in a random order. The data analysis was limited to 1 h before and 1 h after the drug injections. Ten out of the 16 patients showed an IOM motor pattern. The administration of SUM caused a significant increase in the number of swallows (SUM 99.5 +/- 15.4 vs 78.6 +/- 16.1 basal, P = 0.03) and of primary oesophageal motor waves (SUM 89.6 +/- 13.4 vs 67.2 +/- 12.9 basal, P = 0.04) with no significant changes in the percentage of swallows associated with propagation. Placebo was not associated with increase in the number of swallows (80.3 +/- 14.6, P = 0.9) or of primary oesophageal motor waves (70.1 +/- 12.3, P = 0.7). The amplitude and the percentage of propagated oesophageal motor waves as well as the mean basal LOS tone were unaltered by SUM. There was no change in the symptoms reported after SUM. Although effective in healthy subjects, SUM 6 mg s.c. improves only the numbers but not the amplitude or propagation of oesophageal motility of patients with IOM. The 5-HT1 pathway and its acute stimulation seem to play only a minor role in the pathogenesis of such a disease.

摘要

5-羟色胺1(5-HT1)激动剂舒马曲坦(SUM)可使健康受试者的食管运动波幅度及食管下括约肌(LOS)张力增加。本研究旨在评估这种效应在食管动力障碍(IOM)患者中是否也会出现。对16例有胸痛及轻至中度吞咽困难的患者(9例男性,7例女性,年龄范围34 - 55岁)进行了研究;所有患者此前均接受过正常的心脏、放射及上消化道内镜检查。使用电子探头进行食管测压以记录吞咽、食管、LOS及胃的动力。运动模式符合IOM(>30%的运动波幅度<30 mmHg和/或未传导)的患者,以随机顺序在上午和下午皮下注射6 mg SUM或安慰剂。数据分析限于药物注射前1小时和注射后1小时。16例患者中有10例表现出IOM运动模式。注射SUM后,吞咽次数(SUM组99.5±15.4,基础值78.6±16.1,P = 0.03)及原发性食管运动波次数(SUM组89.6±13.4,基础值67.2±12.9,P = 0.04)显著增加,而与传导相关的吞咽百分比无显著变化。安慰剂未使吞咽次数(80.3±14.6,P = 0.9)或原发性食管运动波次数(70.1±12.3,P = 0.7)增加。SUM未改变食管运动波的幅度、传导百分比以及平均基础LOS张力。注射SUM后报告的症状无变化。虽然SUM对健康受试者有效,但皮下注射6 mg SUM仅能改善IOM患者食管动力的次数,而不能改善其幅度或传导。5-HT1途径及其急性刺激似乎在这种疾病的发病机制中仅起次要作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验